Gefitinib (ZD1839)

For research use only. Not for use in humans.

目录号：S1025 别名： Iressa 中文名称：吉非替尼

CAS No. 184475-35-2

Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173、Tyr992、Tyr1173和Tyr992，IC50 分别为37 nM、37nM、26 nM和57 nM。Gefitinib 可通过阻滞PI3K/AKT/mTOR信号通路来促进肺癌细胞的自噬和细胞凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1574.78	现货
100mg	RMB 1227.69	现货
250mg	RMB 2205.98	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Gefitinib (ZD1839)发表文献479篇：

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Theranostics, 2021, 11(2):824-840

PubMed: 33391507 ( click the link to review the publication )

Theranostics, 2021, 11(6):2594-2611

PubMed: 33456562 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E272

PubMed: 33450879 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009221

PubMed: 33471869 ( click the link to review the publication )
Cell Death Dis, 2021, 12(1):83

PubMed: 33446634 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.3555.2020

PubMed: 33355298 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Elife, 2020, 9e60541

PubMed: 32940599 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01465-y

PubMed: 32978523 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3761

PubMed: 33327495 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )
Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):768

PubMed: 32943616 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4251-4265

PubMed: 33414998 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):87

PubMed: 33012785 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:554704

PubMed: 33330026 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )
J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7770

PubMed: 33092268 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Invest New Drugs, 2020, 38(4):1003-1011

PubMed: 31612426 ( click the link to review the publication )

Am J Transl Res, 2020, 12(11):7377-7385

PubMed: 33312374 ( click the link to review the publication )

Infect Immun, 2020, 88(4)e00819-19

PubMed: 31964750 ( click the link to review the publication )

Oncol Rep, 2020, 45(2):459-468

PubMed: 33416163 ( click the link to review the publication )

Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13533

PubMed: 32558328 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13670

PubMed: 32956565 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020,

PubMed: 32843430 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):670

PubMed: 32820157 ( click the link to review the publication )

Fundam Clin Pharmacol, 2020, 10.1111/fcp.12641

PubMed: 33336420 ( click the link to review the publication )
BMC Cancer, 2020, 20(1):1189

PubMed: 33276757 ( click the link to review the publication )

Exp Mol Med, 2020, 10.1038/s12276-020-0474-1

PubMed: 32728068 ( click the link to review the publication )

Cells, 2020, 9(8):E1830

PubMed: 32756527 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107994

PubMed: 32755586 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Cancer Treat Res Commun, 2020, 25:100229

PubMed: 33152554 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )

Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )
Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Mol Cancer, 2019,

PubMed: 31747941 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cells, 2019, 8(12)E1495

PubMed: 31771093 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )

Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Cell Prolif, 2019,

PubMed: 31094020 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )
Biomolecules, 2019, 9(10)E638

PubMed: 31652643 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Mol Carcinog, 2019,

PubMed: 30811684 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Mediators Inflamm, 2019,

PubMed: 32082070 ( click the link to review the publication )
Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Mol Med Rep, 2019,

PubMed: 31638204 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30975694 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2019, 22(5):255-263

PubMed: 31109434 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )
Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

EMBO Rep, 2018,

PubMed: 29335246 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Oncogene, 2018, 37(9):1251-1262

PubMed: 29242605 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018,

PubMed: 29961070 ( click the link to review the publication )
Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):883-895

PubMed: 29633504 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):1775-1786

PubMed: 29624806 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Sci, 2018,

PubMed: 29487179 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )
Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Gen Virol, 2018,

PubMed: 29624161 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1311-1320

PubMed: 29907991 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Cell Mol Biol (Noisy-le-grand), 2018, 64(4):6-10

PubMed: 29631678 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )
Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Neuro-oncology, 2017,

PubMed: 28575494 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Elife, 2017, 6e26733

PubMed: 28737489 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Oncogene, 2017, 36(6):731-745

PubMed: 27477696 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

ACS Infect Dis, 2017, 3(8):564-574

PubMed: 28537707 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28684780 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28939861 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )
Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017,

PubMed: 28927099 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(40):69185-69197

PubMed: 28978189 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22325-22343

PubMed: 28423611 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28427242 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )
Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26640141 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )

Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Anal Biochem, 2016,

PubMed: 27059751 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34395-419

PubMed: 27284014 ( click the link to review the publication )
Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(31):50258-50276

PubMed: 27384680 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Tumour Biol, 2016,

PubMed: 26286833 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27556697 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

EMBO Rep, 2015,

PubMed: 26341626 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2947-58

PubMed: 26089022 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25746002 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Cell Death Dis, 2015,

PubMed: 26469972 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )
Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26268703 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26639561 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Mol Med Rep, 2015,

PubMed: 25483995 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23857-73

PubMed: 26160843 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )
Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Int J Biol Sci, 2014,

PubMed: 25013379 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )
Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Prostate, 2014, 74(5):528-36

PubMed: 24435707 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):2230-6

PubMed: 25175149 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115144

PubMed: 25502225 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277177 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )
JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62852

PubMed: 23696788 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )
Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 2):435-48

PubMed: 22357970 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )

Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

产品安全说明书

EGFR抑制剂选择性比较

生物活性

产品描述

特性

Gefitinib是有效的EGFR酪氨酸激酶抑制剂。

靶点

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

体外研究

Gefitinib 作用于高和低表达EGFR的细胞系，包括NR6, NR6M 和 NR6W 细胞系，有效抑制EGFR上全部酪氨酸磷酸化位点。磷酸化位点 Tyr1173和Tyr992敏感性较低，需要高浓度Gefitinib才能抑制。Gefitinib作用于NR6W细胞，高效阻断PLC-γ磷酸化, IC50为27nM。NR6wtEGFR 和NR6M细胞系具有低水平PLC-γ磷酸化， IC50 分别为 43 nM和 369 nM。Gefitinib抑制AKT磷酸化，作用于低EGFR和EGFRvIII表达的细胞系， IC50 分别为220 和263nM。Gefitinib按 0.1 到 0.5μM剂量处理，显著促进而不是废除 NR6M细胞形成集落。然而, 2μM Gefitinib 完全抑制 NR6M 集落形成。Gefitinib 作用于高和低EGFR表达的细胞系，EGF 刺激72小时后，快速抑制EGFR 和ERK 磷酸化，这种作用存在剂量依赖性。^[1]Gefitinib抑制 EGF驱动的未转化MCF10A 细胞生长，IC50为 20 nM。^[2] Gefitinib 作用于MDA-MB-231细胞，抑制EGF信号。Gefitinib严重抑制细胞数的增多，这种作用存在剂量依赖性。 ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1975	NWHVTY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHO[HJqUUN3ME2yNU41PjFizszN	Mny1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HT	Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorGTWM2OD1{MT60N\|MyKM7:TR?=	M2\ZOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HUTU-80	M2T6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fofmlEPTB;MkGuOFM{PiEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
PA-1	Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXn6cWRWUUN3ME2yNU4zPzh5IN88US=>	Mn;2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HOP-62	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTJzLkK3PFQh\|ryP	NUPqcW1vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GI-1	NF7FW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTJzLkG3JO69VQ>?	Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MC116	NXrsfFdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm3NHhvUUN3ME2yNU4xPzJ\|IN88US=>	MojxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A375	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXOzUGxnUUN3ME2yNU4xPTZ5IN88US=>	M1z4N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
IST-SL1	M1\LfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTJyLke4O\|kh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TE-5	M{O3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTJyLke0PFIh\|ryP	NYnuOIJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SiHa	M4\zRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fyVGlEPTB;MkCuN\|cyOiEQvF2=	MkDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LB2518-MEL	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvjOHVKSzVyPUKwMlM4OzlizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BB49-HNC	M{\BUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf3W2M{UUN3ME2xPU46OiEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HGC-27	NFPRSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fmNGlEPTB;MkCuNVM6PCEQvF2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Becker	NF7ZXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX34SHhlUUN3ME2xPU45PTR5IN88US=>	Mm\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TYK-nu	M{HP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PUemlEPTB;MUmuPFM4QCEQvF2=	NELPV5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H650	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3uRY1SUUN3ME2xPU44PTB6IN88US=>	MlG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
WM-115	NHfhZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTF7Lk[3O\|Qh\|ryP	MmfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HuH-7	NW\JUIJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjMTWM2OD1zOT63OFIyKM7:TR?=	NFKwNnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-N87	M3vzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TqOmlEPTB;MUmuOVk6OiEQvF2=	NYTsNI1oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1048	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTF7LkKzNlYh\|ryP	NVPBSWpLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H446	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj5VGtKSzVyPUG5MlM2QDlizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1437	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfjbFhZUUN3ME2xPU4xPDZ5IN88US=>	NGqzOXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
D-263MG	MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTF7LkCxO\|Ih\|ryP	M4KyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MFH-ino	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XtTWlEPTB;MUiuPVY3QSEQvF2=	NFHq[4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
U-266	M2r5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfT[pBKSzVyPUG4Mlg3PDlizszN	MmTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
OVCAR-8	NYfDd4U6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL0SZhrUUN3ME2xPE46Ojd4IN88US=>	M4HWcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KNS-42	MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF[xfXNKSzVyPUG4MlgxOTVizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
U251	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLHTWM2OD1zOD63N\|Q4KM7:TR?=	NESyPHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MFE-280	Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\QXll{UUN3ME2xPE44Ojl\|IN88US=>	M3X3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1563	NIPuPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTF6LkexNlQh\|ryP	M{ixNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MDA-MB-361	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTF6LkW1PFgh\|ryP	Mm\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HLE	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTF6LkOxOFgh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW982	M3Xje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;NNGlEPTB;MUiuOFA4PSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KM-H2	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrZd29mUUN3ME2xO{46PDFzIN88US=>	M{myclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-502MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2G5SWlEPTB;MUeuPVgxQCEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ES8	NGnYOHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTF5Lki1PVMh\|ryP	NEPJdZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SF268	NHzVVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jHWWlEPTB;MUeuOlk3QSEQvF2=	NYf6ToNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
Calu-6	NH3BW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{P5cmlEPTB;MUeuOlc5OiEQvF2=	NGi1NlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW1783	M2jHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDneWhrUUN3ME2xO{43PDF3IN88US=>	NITXNow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H747	NEjMcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTF5LkWyPVch\|ryP	MnK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1573	NXfubIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTF5LkK4NlYh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1581	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlO2TWM2OD1zNz60OFEyKM7:TR?=	NHzXPFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RKO	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HFV2lEPTB;MUeuNFc1QCEQvF2=	M3;vblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MZ2-MEL	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTF5LkGzN{DPxE1?	NIT0Tog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GI-ME-N	NX[zZZVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\aW2lEPTB;MU[uPVA{OiEQvF2=	NHzwPHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LB373-MEL-D	Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWi5eGhuUUN3ME2xOk44OjN{IN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MEL-HO	NFTyNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHf2cIxKSzVyPUG2Mlg5PTRizszN	MmPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BEN	M4fJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPoWlA4UUN3ME2xOk42OTV3IN88US=>	NU\h[HFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
M059J	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vjXWlEPTB;MU[uNlg1KM7:TR?=	NHXtN4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
D-283MED	Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPy[mNzUUN3ME2xOk41OjB7IN88US=>	M3fI[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
GP5d	M1z5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTF4LkKxPFch\|ryP	NWjOZ4Y4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BHT-101	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoToTWM2OD1zNj6yOFM6KM7:TR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HT55	M1;zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3sO2w1UUN3ME2xOU46PDd6IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
no-11	NYDiXJJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnOXZhKSzVyPUG1Mlk3PjNizszN	M3f5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MPP-89	M1XWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\4fmlEPTB;MUWuPVQyPyEQvF2=	NHzRfXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HuCCT1	M2[4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PUWWlEPTB;MUWuPFc1KM7:TR?=	NGK3Xm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H23	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHCTWM2OD1zNT64OFM5KM7:TR?=	M1L6RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
UMC-11	M4n4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7JTWM2OD1zNT63OVI{KM7:TR?=	NGm1S4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MCF7	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTF3LkixOFUh\|ryP	M2rE[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
COLO-320-HSR	NUTOS5NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPCWnh2UUN3ME2xOU42OzB5IN88US=>	M1TYOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CW-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\0V2tKSzVyPUG1MlE1OjFizszN	NV7ZXlB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MOLT-4	NGjFWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTF3LkC0PVch\|ryP	M1TxS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1755	M3\GN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\sTWM2OD1zND65PVU{KM7:TR?=	M3TmUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MIA-PaCa-2	NWjNeWgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXr0Oo52UUN3ME2xOE46PjlizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TGBC1TKB	MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK1eVJKSzVyPUG0MlY3OTVizszN	NHzDRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H630	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTF2Lkm0Olch\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LAN-6	NH;uWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGr1UW1KSzVyPUG0MlI2OyEQvF2=	MlXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A549	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Lvc2lEPTB;MUSuOFcyOiEQvF2=	NVnKNJl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RD	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF2LkS4NVMh\|ryP	M33ON\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KALS-1	M3TnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHviXVlKSzVyPUGzMlg2OjVizszN	NHnsNWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LOXIMVI	NVLBXHBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXITWM2OD1zMz62NVUyKM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-PN-DW	NYTxSnhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTF\|Lki0Nlch\|ryP	NIK1Spg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SN12C	M3;T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\xXGlEPTB;MUOuN\|gxQCEQvF2=	MkPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1993	M1H2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTF\|LkSyPFUh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
G-361	MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILZTplKSzVyPUGyMlkyOjlizszN	NGq4VnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RH-18	NGfxbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTF\|LkK5OlIh\|ryP	M4LafVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
GT3TKB	MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTF{Lk[zNlch\|ryP	M13ZVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DMS-273	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz1bmFMUUN3ME2xNk45PjN\|IN88US=>	NYH1WFhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
C3A	NW\GPHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTF{LkW3PFUh\|ryP	NVTq[lRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
Daoy	NF22V5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3CS2VKSzVyPUGyMlQ2PDJizszN	Mo\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ABC-1	Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLFZVVKSzVyPUGyMlM1OSEQvF2=	MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KS-1	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\FN2g4UUN3ME2xNk4zQDN{IN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
JAR	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjlV5BZUUN3ME2xNk4{OzZ7IN88US=>	MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAMA-1	NYfhRY5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTF{LkG2N\|Mh\|ryP	MoG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
U-118-MG	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTF{LkK0OFEh\|ryP	NYrsPWZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OE19	M2LkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonJTWM2OD1zMT65N\|Y4KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Mo-T	M3;ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTmPJR2UUN3ME2xNU46PTRzIN88US=>	NET2b\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SCC-9	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3BRVNFUUN3ME2xNU45OTVzIN88US=>	M37QOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HOS	NE\YVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTFzLki2PFMh\|ryP	NWW4NItvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
UM-UC-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nZcmlEPTB;MUGuO\|QzOSEQvF2=	NFrHZoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MMAC-SF	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zHbWlEPTB;MUGuO\|I2OiEQvF2=	NIXGfo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MLMA	NFmyZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIL4R2VKSzVyPUGxMlY6QTdizszN	NV;OTo9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RPMI-7951	NVHVfI82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTFzLk[zOFgh\|ryP	NUjnUpU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1299	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX[ye\|lKUUN3ME2xNU43PjR5IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LS-411N	NYLYS4JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fPXWlEPTB;MUGuOlExOSEQvF2=	NFS3cpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1954	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrsb4RKSzVyPUGxMlQ{PiEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
GOTO	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rSR2lEPTB;MUGuOVIxPiEQvF2=	NF;COoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
FTC-133	M2\rUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHTTWM2OD1zMT6zNFgyKM7:TR?=	NHLPRY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LB831-BLC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfUNY1KSzVyPUGxMlI2PTZizszN	M4LwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HCC38	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7iTWM2OD1zMD65O\|E3KM7:TR?=	NEjoTJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SF-295	M4iwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TqZmlEPTB;MUCuPVkxOiEQvF2=	NEnlflY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
K-562	M4mzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPvTWM2OD1zMD64N\|k2KM7:TR?=	MljLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW900	NUfxZYJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTFyLkiyNlgh\|ryP	NWSxfVcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
D-336MG	NXXwfFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnq0TWM2OD1zMD63NFA2KM7:TR?=	M1rZTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LXF-289	M1u2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HqbmlEPTB;MUCuO\|k3PyEQvF2=	NYn4ZYZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SW962	M4nYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYj3UmRSUUN3ME2xNE43OjB2IN88US=>	MnfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
VMRC-RCZ	Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTFyLk[3OFkh\|ryP	MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HEC-1	MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlO2TWM2OD1zMD60NFgyKM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A2058	NHn1NZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XYS2lEPTB;MUCuOVQ6OSEQvF2=	M2S1UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
K5	M1TlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTFyLkOzPVUh\|ryP	M2HR[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
U031	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zaUmlEPTB;MUCuNlY5PiEQvF2=	NWXyN3BGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
YH-13	M1;HU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\ZTWM2OD1zMD6zNFU4KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-UT-1	M2TaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Hz[WlEPTB;MUCuNlU4PCEQvF2=	M4nnOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H810	NUfwR2dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULIe486UUN3ME2xNE4yPTl5IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DJM-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTFyLkG3N\|Ih\|ryP	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAL-51	M4PBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHiwdGhKSzVyPUGwMlA5PzdizszN	MoDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HCE-4	NFv6WYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vzOWlEPTB;MUCuNVEzOiEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2342	M{\NN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjWbpZKSzVyPUGwMlAyPTVizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A204	NV3jXpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfsW3ZKSzVyPUGwMlA1PjZizszN	NH3sWno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1355	NHTyOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLQUopbUUN3ME25Mlk1ODh6IN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW837	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XtOmlEPTB;OT64OFgzKM7:TR?=	M3KyZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
OCI-AML2	M4HzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\zOm8zUUN3ME25Mlg3QTZizszN	NYHobWQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EFO-21	NIHRXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTY[\|ZkUUN3ME25MlU5PzN3IN88US=>	M3nhUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
C32	NHLmSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\iZWlEPTB;OT62N\|M1KM7:TR?=	NG\ZVIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KP-4	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\iTWM2OD17LkS4PFM5KM7:TR?=	NX7WXnpNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A101D	NXj6fFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTlwNUG3NVkh\|ryP	M3m5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
IA-LM	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTlwNEG5OlYh\|ryP	Mm\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HPAF-II	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTlwMkK1NVgh\|ryP	M{\tZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
Capan-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTlwNECxNFkh\|ryP	MkHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BFTC-909	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTlwMUiyPVch\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RPMI-8226	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:xU3JzUUN3ME25MlEyOzB2IN88US=>	M4H6UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
ChaGo-K-1	NVTWd41IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M36wWGlEPTB;OT6xNFU4QSEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2228	NUPUUY1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml[yTWM2OD17LkGxNFgyKM7:TR?=	Ml7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H226	NUjqWXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3PdW5KSzVyPUmuNFkh\|ryP	NEnsVmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
D-566MG	MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3wWpVKSzVyPUmuNFE5OSEQvF2=	MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LS-1034	NH2zd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmC1TWM2OD16Lkm0OlUzKM7:TR?=	MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1792	M4rMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PKNmlEPTB;OD64PFkxOyEQvF2=	NWf5TpNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
COLO-792	M33ZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRThwN{S5OFYh\|ryP	M2LNclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
A673	NIOydYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRThwNke2NVEh\|ryP	NGjlN2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
D-392MG	NUnlV\|lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nq[2lEPTB;OD62OlIyPCEQvF2=	MlnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
EGI-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRThwNkCwPFgh\|ryP	NV3OdWlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TGBC11TKB	NIDRSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PMXWlEPTB;OD60OlE3PCEQvF2=	MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
5637	NULURZFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\Ue2lEPTB;OD6zNVA2PSEQvF2=	NXzHc\|U{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KYSE-70	NVzMfml{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzlZWxEUUN3ME24MlE6PzZzIN88US=>	M2fSUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
VM-CUB-1	NF\FRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRThwMUewNlkh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
AM-38	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLOTWM2OD16LkG2Nlgh\|ryP	M3nFWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H661	NXzySmtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTCTWM2OD16LkC1PFY4KM7:TR?=	Mk\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SHP-77	MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHntUYpKSzVyPUeuPFY3PTNizszN	MoKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DK-MG	NFvUb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnGTWM2OD15LkizNlAyKM7:TR?=	M33lWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NB13	NFe4VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTdwOEK2Olch\|ryP	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
COLO-829	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj0T5FKSzVyPUeuOlY1PjNizszN	NVvxVndtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OS-RC-2	M1voOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3L1cWlEPTB;Nz60PVg6PCEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC1419	M37mU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXMNmZKSzVyPUeuOFY5OzNizszN	M{K3TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SKG-IIIa	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm4TWM2OD15LkS1N\|gyKM7:TR?=	NFLGZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
COLO-668	NXHqS2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrUTHd7UUN3ME23MlQ{QTZ5IN88US=>	M4DWZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-62	NVW0NoZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PzSGlEPTB;Nz6zPVg3PiEQvF2=	NVi2bHpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HEL	NXLEPGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIf2O41KSzVyPUeuN\|c2OjFizszN	M1\KVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H2030	M3i5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\2c2dKSzVyPUeuN\|M3QThizszN	NWnOdYZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
DMS-114	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWr6TGcyUUN3ME23MlI6PjNzIN88US=>	M2PiN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NOS-1	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfETWM2OD15LkK1PFI5KM7:TR?=	M{\hUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KP-N-YS	NUfxR2NCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvudGxrUUN3ME23MlE5OTRizszN	NWPYTXVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OVCAR-4	NF3IRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXLTWM2OD15LkG1N\|Uh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2405	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTdwMEizPVMh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TE-11	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjLTWM2OD15LkC0PVY4KM7:TR?=	M2XBeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KLE	NI\sc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTZwOU[1NVYh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A388	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nqVWlEPTB;Nj64PVUzKM7:TR?=	NUnBc4NKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NB12	MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLKUJJJUUN3ME22Mlc5PDB2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
PFSK-1	NFPZXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjMNJpKSzVyPU[uO\|M1PzhizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-HEP-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnLXHlHUUN3ME22MlcyPzV\|IN88US=>	M4nJR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
Calu-3	MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTZwNkW1Olgh\|ryP	MnjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SH-4	M4\xVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfQRnhKSzVyPU[uOVg5PDRizszN	NYrmTXl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GCT	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XPS2lEPTB;Nj61N\|M5PyEQvF2=	NFLYeVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MSTO-221H	M2[3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7TNYJKSzVyPU[uOVEyPyEQvF2=	NWHK[4JuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GAMG	NYq1UoRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrwSnB5UUN3ME22MlUxPjJizszN	M3zUS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-120	NIXtd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7ydGNEUUN3ME22MlQ2OTZ{IN88US=>	NX:xbFZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	NIO2SZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIexRVJKSzVyPU[uN\|A1PjJizszN	M{nZN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-MEL-28	NH[ydXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFH1Z\|lKSzVyPU[uNlA6PjdizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
8-MG-BA	NGrh[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nBNWlEPTB;Nj6xPVM4QSEQvF2=	M1XhZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
L-428	M4XYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnq0TWM2OD14LkG4NFM4KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
Mewo	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvTTWM2OD14LkGxOFg4KM7:TR?=	M13xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RCM-1	NVjWeYhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnn2TWM2OD14LkC3O\|E6KM7:TR?=	NGP2OmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KE-37	NEXPOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTZwMEeyOVgh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TE-10	M2j0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HtVWlEPTB;Nj6wOFg{OyEQvF2=	NXX2cotFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HDLM-2	NYr0XGRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrsTWM2OD14LkCxOFg6KM7:TR?=	M4HIXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAKI-1	NV;VcJdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTZwMEC5PFUh\|ryP	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RT-112	NYLGPJRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTVwOUCyOFUh\|ryP	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC2998	NEeyPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzafW5KSzVyPUWuO\|E5PzdizszN	NVLhSZByRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCC1187	NEC2eGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTVwN{GwN\|Ih\|ryP	M1fJclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HD-MY-Z	NGPUR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTVwNki1PFEh\|ryP	NIqyWmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RMG-I	NGjZS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[3TWM2OD13Lk[1PVQzKM7:TR?=	NInnSXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BFTC-905	NWLwR3BXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LoNGlEPTB;NT62OVg4QCEQvF2=	NGDTcJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW1990	M1;hWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfRTWM2OD13Lk[yNlg2KM7:TR?=	NFLwfo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW13	M{\tW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnaTWM2OD13LkWzNlY2KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
AGS	NUX3S4k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3W5RmlEPTB;NT60PVYyQCEQvF2=	NYfiVIFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
ATN-1	NYryWGlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[wS3IyUUN3ME21MlQyOTh2IN88US=>	M2LrWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CGTH-W-1	MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrCTWM2OD13LkO4OVg1KM7:TR?=	M2XGSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NOMO-1	M3TzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\kV2lEPTB;NT6yN\|E4PiEQvF2=	M1\VUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
ALL-PO	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS5TWM2OD13LkKyOVg4KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KP-N-YN	NWXtfmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzqTWM2OD13LkGyOVkyKM7:TR?=	NFOyVW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1838	NVS2e3NyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPBcXBvUUN3ME21MlAzODd4IN88US=>	NHrnXIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-9	M1TwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LPT2lEPTB;NT6wNVUzPSEQvF2=	M4[yZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KOSC-2	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEGyeGtKSzVyPUSuPVk6PTlizszN	NFH3WHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ES1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHMUVdKSzVyPUSuPVYxOzVizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KNS-62	NFqyeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTRwOUC4NFch\|ryP	M3rqS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KYSE-520	NV20bWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTRwOEiwNVgh\|ryP	M2rZVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
P30-OHK	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnCRZZKSzVyPUSuPFE6OjlizszN	NWnPZ4dFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NB10	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPkZYlKSzVyPUSuOVk4QDFizszN	NXjZN29qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A172	NUe3TIZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjzOG9RUUN3ME20MlU2PTJzIN88US=>	MnTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-OV-3	NEjiU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfYTWM2OD12LkS2NFQzKM7:TR?=	NFmzN2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GR-ST	NIfFdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKxPZRKSzVyPUSuOFMyQCEQvF2=	NFLKPZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1937	M4DuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzGTWM2OD12LkO3PVk{KM7:TR?=	MmL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LU-139	NVy3fG06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfyTWM2OD12LkO3NlQ4KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SNU-C2B	NH7yWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTRwM{S2PFYh\|ryP	NF\kOY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KARPAS-299	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\uSW1KSzVyPUSuN\|ExOTNizszN	NV\5[\|lSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EW-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ridGlEPTB;ND6xN\|I3OSEQvF2=	NUjydZk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HL-60	M2m3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\J[JZCUUN3ME20MlEzOjRzIN88US=>	NXf5TVZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TCCSUP	NWjuRmhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTRwMUGwOUDPxE1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RCC10RGB	NXTpPZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXafpBKSzVyPUSuNFEzPDZizszN	NYXDNWw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H441	M{[2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\pXXc4UUN3ME2zMlk4ODF2IN88US=>	M1PpbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EW-16	NF3WSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrFXZJKSzVyPUOuPVU2PzdizszN	M2\ze\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
JVM-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fSW2lEPTB;Mz65OFc2OiEQvF2=	MkmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NH-12	M2npR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPjTWM2OD1\|Lkm0NVg4KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
IST-MES1	NY\G[2NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\uOppyUUN3ME2zMlk1ODJ7IN88US=>	M1z3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H69	MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTNwOUCxO\|gh\|ryP	NV3mRnV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KURAMOCHI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\RO2lEPTB;Mz64OlA2PiEQvF2=	MmmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1155	M3;HTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTNwOESxOVkh\|ryP	NHH3PVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H28	M3zOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTNwOEK5OlEh\|ryP	NHzyRnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ES4	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXweXdKSzVyPUOuPFIzQDZizszN	NF\Zdpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjOWJJFUUN3ME2zMlc2PDB4IN88US=>	M2DFc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
PANC-10-05	Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTNwN{KwO\|Ih\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SK-MES-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVr2[pFkUUN3ME2zMlY1PjF2IN88US=>	NY\6R2FIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
C2BBe1	NUKxNYxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfCTWM2OD1\|Lk[0OFA4KM7:TR?=	M{XtSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
A2780	M4nNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTNwNkSwPFkh\|ryP	NY[xWGVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CaR-1	NEfTV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rJbWlEPTB;Mz62NVA1QCEQvF2=	NEXXSnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-LU-1	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoW0TWM2OD1\|Lk[wOlQ2KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OAW-28	NYPJSWZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvlcHVKSzVyPUOuOVk1OjZizszN	NYDHeIpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TE-1	Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnPU4NoUUN3ME2zMlU6OTZ7IN88US=>	NFzuTWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
639-V	NV7jbnhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYSz[\|ZxUUN3ME2zMlU4Pzl{IN88US=>	Mmm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
C8166	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTNwNE[1NlEh\|ryP	MmXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NTERA-S-cl-D1	NGD0UXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7KTWM2OD1\|LkS0PVU4KM7:TR?=	M3r1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-542MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjWRmdKSzVyPUOuOFQzOjJizszN	NWXwPHBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LB771-HNC	MoDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;UPVM5UUN3ME2zMlM6OTJ4IN88US=>	NF7xeJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H727	M1\mUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTNwM{i1PFQh\|ryP	MoWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1463	NIDPdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfoU4xTUUN3ME2zMlI3OTl{IN88US=>	MkPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1793	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTNwMkGwPVgh\|ryP	MkDvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HT-1376	M3;qU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3qb\|BKSzVyPUOuNlA2ODZizszN	M4npeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
647-V	M{OzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnQTWM2OD1\|LkG2NlIh\|ryP	NX6xempZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BCPAP	Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTNwMEiyPVUh\|ryP	NEnScZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MN-60	M1XmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILDXHVKSzVyPUOuNFQ6PzRizszN	NX7oR4VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
COLO-680N	NH3sToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PUVmlEPTB;Mz6wNFQ6PSEQvF2=	NILk[\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DU-4475	NWCzcFNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV[3WodrUUN3ME2yMlk6ODV{IN88US=>	MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1693	NVTEc2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGX6WnhKSzVyPUKuPVU5QTdizszN	Mmf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HC-1	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M132VWlEPTB;Mj65OFAyOiEQvF2=	NV;BWXk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KYSE-510	M2T6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLPV2VKSzVyPUKuPFY4QDZizszN	MlL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
OVCAR-3	NHjwUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO4eJRCUUN3ME2yMlg2PTl2IN88US=>	MnPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
PC-3	NXroU5RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;u[mlEPTB;Mj64N\|MyPyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BB65-RCC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7GbWRsUUN3ME2yMlgxPzF\|IN88US=>	M17NOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
QIMR-WIL	NYj5[mg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUf0OHExUUN3ME2yMlc2QTV{IN88US=>	M3\UclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HuP-T4	NVXyU4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfmeVM4UUN3ME2yMlczQDF6IN88US=>	M1yzVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
Detroit562	NX3FbGdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHBZXBKSzVyPUKuOlk5PDVizszN	M3rLfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DMS-79	NUCwXWJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{PC[WlEPTB;Mj62PVI5PCEQvF2=	M3jvPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MC-IXC	NHfWcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJwNkS0OVMh\|ryP	M3\WSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TE-8	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELtc2xKSzVyPUKuOlM3PTNizszN	NVnwTmV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MKN7	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHFTWM2OD1{Lk[yO\|Q5KM7:TR?=	M1ywdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HH	M3nvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HGSWlEPTB;Mj60PVg2PCEQvF2=	NEPXUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CFPAC-1	NYi1R4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXFTWM2OD1{LkSzPFY1KM7:TR?=	MoHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HTC-C3	NUfQfoptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{eyOmlEPTB;Mj60NlI3PyEQvF2=	NF;VdGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NY	NH\zO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTaVVZ4UUN3ME2yMlM4OjdizszN	M4XhZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KU812	NFfRTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPzZXJNUUN3ME2yMlM3Pzd7IN88US=>	NFfkZ\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
EW-18	NXPZOo5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LFO2lEPTB;Mj6zOVQ4OSEQvF2=	Ml3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H2170	M3\ZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkS1TWM2OD1{LkO0O\|g{KM7:TR?=	NWfvZoZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
JVM-3	NH3SOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkC5TWM2OD1{LkO0OlQ{KM7:TR?=	NXvTbG81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
IGROV-1	NITv[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPlTWM2OD1{LkOxNlM4KM7:TR?=	NXvtc2FyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
A498	M4rnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4naeWlEPTB;Mj6yPVQyPSEQvF2=	NV\iRZcxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BT-20	NYDMR5VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXu2bGRWUUN3ME2yMlI3PzR2IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SCC-4	M2n4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7zTWM2OD1{LkKxO\|c3KM7:TR?=	NIWy[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
786-0	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ftTmlEPTB;Mj6xPFQxPiEQvF2=	M{[3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RXF393	M{LKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvjTWM2OD1{LkGzNFM3KM7:TR?=	NUDmZVc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KARPAS-45	NWjxR\|JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37ESGlEPTB;Mj6xNlQ4QSEQvF2=	MnrOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RPMI-8866	NXW2TIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjPdFRKSzVyPUKuNFg1QDFizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2009	NEjnXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTJwME[yNVQh\|ryP	NFO2SnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW1116	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTJwME[wNFkh\|ryP	M37VUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EKVX	NWC4XG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfGNo5KSzVyPUKuNFQ6OzlizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TGBC24TKB	NE\GflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\rUHF1UUN3ME2yMlAzQTZzIN88US=>	NWrCbXZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CAL-12T	NVH2U3BpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLONXE3UUN3ME2yMlAyQDZzIN88US=>	MlTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HCC70	NVqzRXUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3tTWM2OD1{LkCwPFE2KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OMC-1	NHLWUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XQ[2lEPTB;MT65PVg5QCEQvF2=	NYK2PZNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EPLC-272H	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHYbFNKSzVyPUGuPFU2PDlizszN	MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H209	MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\tb49KSzVyPUGuO\|czPjlizszN	MlHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1666	M4K1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;aRmlEPTB;MT63OFcxPCEQvF2=	MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
COLO-678	NX\6dI52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPlTWM2OD1zLkezOFQ1KM7:TR?=	M2nldVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
PANC-03-27	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnT4TWM2OD1zLkewNVM6KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BB30-HNC	Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LBdmlEPTB;MT62PFk4OiEQvF2=	NXvHW2l6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
ML-2	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVz4cGVmUUN3ME2xMlY1ODJ7IN88US=>	NV3mRoRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BT-549	NWW3OZZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mle1TWM2OD1zLkW4O\|Q4KM7:TR?=	M4rtclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HSC-3	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\LdGlEPTB;MT61OFM5KM7:TR?=	MlfPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LAMA-84	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfUc5RQUUN3ME2xMlU{QDF3IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SCC-25	NVHwbVk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEKzcm1KSzVyPUGuOVI{OjJizszN	M17PW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SAS	NH3DdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjTTWM2OD1zLkWxOlIzKM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BE-13	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrFTWM2OD1zLkWwOlcyKM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
J82	NYHvV\|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLtTWM2OD1zLkS1O\|Y3KM7:TR?=	NWSzUItORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
697	M12yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTBW\|dWUUN3ME2xMlQ1OTB2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H526	Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHJbm5KSzVyPUGuOFM5OjZizszN	NVvtVlZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RH-1	MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPkdpRKSzVyPUGuOFEyOzZizszN	NUXZUYp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	M3rwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTFwNEGxNUDPxE1?	NWrQSY5YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NB5	M1yxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\FS4NyUUN3ME2xMlQxQDl2IN88US=>	NILBT\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KMOE-2	NYHXPFI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTFwM{m4NVUh\|ryP	MmDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-N-DZ	M4rmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEixdWVKSzVyPUGuN\|Y6PDdizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW48	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1KxdGlEPTB;MT6zOlYyQCEQvF2=	NVeydoNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SW954	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\ncJNKSzVyPUGuN\|QxPDhizszN	Mn6zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1650	M4DzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zIbWlEPTB;MT6zN\|Q5OiEQvF2=	NV3zSIFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NKM-1	Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GxXmlEPTB;MT6zNlU6PyEQvF2=	NGLFO4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1092	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2S2NmlEPTB;MT6zNFg2KM7:TR?=	NYexeHR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CTV-1	NH\vNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPvTWM2OD1zLkOwPEDPxE1?	NFn3NoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GCIY	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELVe4pKSzVyPUGuN\|AyOzJizszN	MkTBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1088	M3nRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXxTWM2OD1zLkK5OlA4KM7:TR?=	M3zlW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
769-P	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIn6XmdKSzVyPUGuNlc6OThizszN	MmnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
OAW-42	MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\STWM2OD1zLkK3PFI2KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SNU-449	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInCSIdKSzVyPUGuNlIzODhizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MKN1	M3\tW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n2cWlEPTB;MT6yNVk5PyEQvF2=	NVS2SWtNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1648	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlviTWM2OD1zLkGwOlE3KM7:TR?=	NYjXWG81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KU-19-19	Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYD6Wnp[UUN3ME2xMlA5PTRzIN88US=>	NX3aeFFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MHH-PREB-1	NXTSXI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTFwMEi0OVEh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EM-2	M{Pp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DjOGlEPTB;MT6wN\|AyPiEQvF2=	M1zFOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1304	NYHUdmZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3GzemlEPTB;MT6wNVY1OyEQvF2=	NFPVPVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DOHH-2	NUjBeJBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkKzTWM2OD1zLkCwNFIyKM7:TR?=	MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MS-1	NV7aUo5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3KTWM2OD17OUSuOlkhdk1?	M2TOelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-NEP-1	M1XQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vI[mlEPTB;OUi5MlQ1KG6P	NUXIVmM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HT-3	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn6yTWM2OD17OEKuOFEhdk1?	NXvoVXhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BHY	MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;oUWlEPTB;OUe1MlQ5KG6P	M4HiOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BT-474	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn5ZYNIUUN3ME25N\|gvOTRibl2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAPAN-1	NVW2ZWIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrtTWM2OD16OEOuNlkhdk1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H2126	M1HR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfVd3dXUUN3ME24PFIvQDNibl2=	NVO3U3lMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
COR-L88	NW\pRWU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17sNWlEPTB;OEiyMlI3KG6P	MmTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DEL	NH;NZWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInwZnJKSzVyPUi3O{43PSCwTR?=	M2PQSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
AU565	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[5THNKSzVyPUi2PU43KG6P	MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
23132-87	M2X6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTh4ND6yPEBvVQ>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LoVo	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTVTWM2OD16NUmuNFYhdk1?	NFzKWGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-12	M3jnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[wTWM2OD16MkGuNVEhdk1?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-

研究领域

产品类型